Novartis is reportedly in talks with Medicines Co. about a potential buyout, although there’s no guarantee a deal will be reached.
Medicines Co. is developing an injectable drug, called inclisiran, that showed in a late-stage study that it cut bad cholesterol in half over 18 months. The drug would fit in with Novartis’ rapidly growing heart failure drug, Entresto.
Shares of Medicines Co. more than tripled this year, leaving the drugmaker with a market value of about $4.7 billion, according to Bloomberg.
Read the full article here.
More articles on pharmacy:
Drugmakers could lose $1T in sales and still be most profitable industry, analysis finds
CAR-T costs ‘not sustainable’ for hospitals, researchers say
How Walgreens, CVS see the future of pharmacy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.